121 related articles for article (PubMed ID: 28334319)
1. ERBB4 acts as a suppressor in the development of hepatocellular carcinoma.
Liu Y; Song L; Ni H; Sun L; Jiao W; Chen L; Zhou Q; Shen T; Cui H; Gao T; Li J
Carcinogenesis; 2017 Apr; 38(4):465-473. PubMed ID: 28334319
[TBL] [Abstract][Full Text] [Related]
2. Expression and inhibitory role of TIMP-3 in hepatocellular carcinoma.
Shen B; Jiang Y; Chen YR; Zheng HC; Zeng W; Li YY; Yin A; Nie Y
Oncol Rep; 2016 Jul; 36(1):494-502. PubMed ID: 27222429
[TBL] [Abstract][Full Text] [Related]
3. GSTZ1 deficiency promotes hepatocellular carcinoma proliferation via activation of the KEAP1/NRF2 pathway.
Li J; Wang Q; Yang Y; Lei C; Yang F; Liang L; Chen C; Xia J; Wang K; Tang N
J Exp Clin Cancer Res; 2019 Oct; 38(1):438. PubMed ID: 31666108
[TBL] [Abstract][Full Text] [Related]
4. Genetic variants in ERBB4 is associated with chronic hepatitis B virus infection.
Liu Y; Zhou Q; He XS; Song LM; Chen L; Jiao WJ; Shen T; Yao S; Wu H; Hu ZB; Gao TM; Li JM
Oncotarget; 2016 Jan; 7(4):4981-92. PubMed ID: 26701850
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory role of Smad7 in hepatocarcinogenesis in mice and in vitro.
Wang J; Zhao J; Chu ES; Mok MT; Go MY; Man K; Heuchel R; Lan HY; Chang Z; Sung JJ; Yu J
J Pathol; 2013 Aug; 230(4):441-52. PubMed ID: 23625826
[TBL] [Abstract][Full Text] [Related]
6. Abberent expression of NOR1 protein in tumor associated macrophages contributes to the development of DEN-induced hepatocellular carcinoma.
Chen S; Zheng P; Wang W; Yi M; Chen P; Cai J; Li J; Peng Q; Ban Y; Zhou Y; Zeng Z; Li X; Xiong W; Li G; Xiang B
J Cell Physiol; 2018 Jun; 233(6):5002-5013. PubMed ID: 29227538
[TBL] [Abstract][Full Text] [Related]
7. BCL2L10 inhibits growth and metastasis of hepatocellular carcinoma both in vitro and in vivo.
Bai Y; Wang J; Han J; Xie XL; Ji CG; Yin J; Chen L; Wang CK; Jiang XY; Qi W; Jiang HQ
Mol Carcinog; 2017 Mar; 56(3):1137-1149. PubMed ID: 27770580
[TBL] [Abstract][Full Text] [Related]
8. Downregulated Expression of PTPN9 Contributes to Human Hepatocellular Carcinoma Growth and Progression.
Hu B; Yan X; Liu F; Zhu C; Zhou H; Chen Y; Liu J; Gu X; Ni R; Zhang T
Pathol Oncol Res; 2016 Jul; 22(3):555-65. PubMed ID: 26715439
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-98 acts as a tumor suppressor in hepatocellular carcinoma via targeting SALL4.
Zhou W; Zou B; Liu L; Cui K; Gao J; Yuan S; Cong N
Oncotarget; 2016 Nov; 7(45):74059-74073. PubMed ID: 27677076
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-548a-5p promotes proliferation and inhibits apoptosis in hepatocellular carcinoma cells by targeting Tg737.
Zhao G; Wang T; Huang QK; Pu M; Sun W; Zhang ZC; Ling R; Tao KS
World J Gastroenterol; 2016 Jun; 22(23):5364-73. PubMed ID: 27340352
[TBL] [Abstract][Full Text] [Related]
11. miR-383 inhibits hepatocellular carcinoma cell proliferation via targeting APRIL.
Chen L; Guan H; Gu C; Cao Y; Shao J; Wang F
Tumour Biol; 2016 Feb; 37(2):2497-507. PubMed ID: 26385772
[TBL] [Abstract][Full Text] [Related]
12. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
13. H2.0-like homeobox 1 acts as a tumor suppressor in hepatocellular carcinoma.
Liu T; Chen J; Xiao S; Lei X
Tumour Biol; 2016 May; 37(5):6419-28. PubMed ID: 26631039
[TBL] [Abstract][Full Text] [Related]
14. STAT3 and AKT signaling pathways mediate oncogenic role of NRSF in hepatocellular carcinoma.
Ma M; Zhou Y; Sun R; Shi J; Tan Y; Yang H; Zhang M; Shen R; Xu L; Wang Z; Fei J
Acta Biochim Biophys Sin (Shanghai); 2020 Oct; 52(10):1063-1070. PubMed ID: 32556117
[TBL] [Abstract][Full Text] [Related]
15. RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma.
Wang F; Feng Y; Li P; Wang K; Feng L; Liu YF; Huang H; Guo YB; Mao QS; Xue WJ
Oncotarget; 2016 Jan; 7(4):4279-97. PubMed ID: 26701853
[TBL] [Abstract][Full Text] [Related]
16. Decreased expression of PBLD correlates with poor prognosis and functions as a tumor suppressor in human hepatocellular carcinoma.
Li A; Yan Q; Zhao X; Zhong J; Yang H; Feng Z; Du Y; Wang Y; Wang Z; Wang H; Zhou Y; Liu S; Nie Y
Oncotarget; 2016 Jan; 7(1):524-37. PubMed ID: 26594798
[TBL] [Abstract][Full Text] [Related]
17. PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma.
Liu WR; Tian MX; Yang LX; Lin YL; Jin L; Ding ZB; Shen YH; Peng YF; Gao DM; Zhou J; Qiu SJ; Dai Z; He R; Fan J; Shi YH
Oncotarget; 2015 Jan; 6(2):846-61. PubMed ID: 25514599
[TBL] [Abstract][Full Text] [Related]
18. B cell CLL/lymphoma 6 member B inhibits hepatocellular carcinoma metastases in vitro and in mice.
Wang J; Dong L; Xu L; Chu ES; Chen Y; Shen J; Li X; Wong CC; Sung JJ; Yu J
Cancer Lett; 2014 Dec; 355(2):192-200. PubMed ID: 25218345
[TBL] [Abstract][Full Text] [Related]
19. Metallothionein 1H (MT1H) functions as a tumor suppressor in hepatocellular carcinoma through regulating Wnt/β-catenin signaling pathway.
Zheng Y; Jiang L; Hu Y; Xiao C; Xu N; Zhou J; Zhou X
BMC Cancer; 2017 Feb; 17(1):161. PubMed ID: 28241806
[TBL] [Abstract][Full Text] [Related]
20. Upregulated in Hepatitis B virus-associated hepatocellular carcinoma cells, miR-331-3p promotes proliferation of hepatocellular carcinoma cells by targeting ING5.
Cao Y; Chen J; Wang D; Peng H; Tan X; Xiong D; Huang A; Tang H
Oncotarget; 2015 Nov; 6(35):38093-106. PubMed ID: 26497554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
